Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
The 2nd US Circuit Court of Appeals in Manhattan has breathed new life into an antitrust lawsuit brought by Regeneron Pharmaceuticals against Novartis. The lawsuit centers around prescription treatments aimed at addressing a condition that can result in severe eye disorders, potentially leading to permanent blindness.
The decision, rendered on Monday, marked a pivotal moment in the ongoing legal battle between the pharmaceutical giants. The appeals court ruled that a lower court judge had erred in dismissing Regeneron’s lawsuit, citing the incorrect application of legal standards to the claims put forth by the plaintiff.
The dispute between Regeneron and Novartis underscores the high stakes involved in the development and commercialization of treatments for critical medical conditions. At the heart of the lawsuit are allegations of anticompetitive behavior by Novartis, aimed at stifling competition and maintaining a dominant position in the market for prescription therapies targeting the identified eye disorder.
Read more: Paris Appeals Court Overturns Novartis, Roche $475M Antitrust Fine
The precise nature of the alleged antitrust violations has not been fully disclosed, but Regeneron’s contentions suggest a concerted effort by Novartis to undermine competition and impede the market entry of rival treatments. Such tactics, if proven, could have far-reaching implications for the pharmaceutical industry, particularly in the realm of specialized medications addressing complex medical needs.
Source: Reuters
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI